Care este prețul pentru ABVC BioPharma, Inc. (ABVC)

Prețul pentru ABVC BioPharma, Inc. (ABVC) este $0.9403

Care este capitalizarea de piață pentru ABVC BioPharma, Inc. (ABVC)

Capitalizarea de piață pentru ABVC BioPharma, Inc. (ABVC) este $24.45M

Venituri ABVC BioPharma, Inc. (ABVC)

ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on creating novel drugs and medical devices to address critical, underserved healthcare requirements across the United States. The company's pipeline includes several key candidates: ABV-1501, currently undergoing Phase I/II clinical trials, is being developed as a combination treatment for triple-negative breast cancer. ABV-1504 has successfully completed Phase II clinical trials for major depressive disorders. ABV-1505 is progressing through Phase II clinical studies for attention deficit hyperactivity disorder (ADHD). ABV-1703 has concluded its Phase I clinical trials for the treatment of pancreatic cancer. ABV-1702 has also finished Phase I clinical investigations for myelodysplastic syndromes. ABV-1601 is in Phase I/II clinical trials, aimed at alleviating depression in individuals with cancer. ABV-1701 Vitargus is in development to treat conditions such as retinal detachment or vitreous hemorrhage. ABVC BioPharma maintains strategic alliances, including a co-development arrangement with Rgene Corporation, alongside collaborative agreements with BioHopeKing Corporation and BioFirst Corporation. The company's headquarters are located in Fremont, California, and it operates as a subsidiary of YuanGene Corporation.

An	Venituri	Schimbă
Nu sunt suficiente date pentru perioada selectată.

Venituri

Schimbă

Nu sunt suficiente date pentru perioada selectată.

Companie	Venituri	Diferență de venituri	Țara
Vertex Pharmaceuticals Incorporated VRTX.US	$12.62B	-	US
Argenx SE ARGX.US	$6.02B	-	NL
Moderna, Inc. MRNA.US	$2.23B	-	US
CSL Limited CSL.AX	$15.70B	-	AU
Lonza Group AG LONN.SW	-	-	CH

Companie

Venituri

Diferență de venituri

Țara